CN101597326B - kahalalide F 及相关化合物 - Google Patents

kahalalide F 及相关化合物 Download PDF

Info

Publication number
CN101597326B
CN101597326B CN200810178807.9A CN200810178807A CN101597326B CN 101597326 B CN101597326 B CN 101597326B CN 200810178807 A CN200810178807 A CN 200810178807A CN 101597326 B CN101597326 B CN 101597326B
Authority
CN
China
Prior art keywords
val
thr
ile
phe
dhb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200810178807.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN101597326A (zh
Inventor
F·阿贝利西奥
E·吉拉尔特
J·C·吉梅内滋
A·洛佩滋
I·曼扎纳雷斯
I·罗德里古斯
M·罗尤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of CN101597326A publication Critical patent/CN101597326A/zh
Application granted granted Critical
Publication of CN101597326B publication Critical patent/CN101597326B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Optical Record Carriers And Manufacture Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Detergent Compositions (AREA)
  • Saccharide Compounds (AREA)
CN200810178807.9A 2000-02-09 2001-02-09 kahalalide F 及相关化合物 Expired - Fee Related CN101597326B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0002952.0A GB0002952D0 (en) 2000-02-09 2000-02-09 Process for producing kahalalide F compounds
GB0002952.0 2000-02-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN01807743A Division CN1422278A (zh) 2000-02-09 2001-02-09 kahalalide F及相关化合物

Publications (2)

Publication Number Publication Date
CN101597326A CN101597326A (zh) 2009-12-09
CN101597326B true CN101597326B (zh) 2014-07-09

Family

ID=9885232

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200810178807.9A Expired - Fee Related CN101597326B (zh) 2000-02-09 2001-02-09 kahalalide F 及相关化合物
CN01807743A Pending CN1422278A (zh) 2000-02-09 2001-02-09 kahalalide F及相关化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN01807743A Pending CN1422278A (zh) 2000-02-09 2001-02-09 kahalalide F及相关化合物

Country Status (27)

Country Link
US (2) US7482429B2 (enExample)
EP (3) EP2258715A1 (enExample)
JP (1) JP5188665B2 (enExample)
KR (1) KR100871489B1 (enExample)
CN (2) CN101597326B (enExample)
AT (1) ATE371667T1 (enExample)
AU (1) AU783542B2 (enExample)
BG (1) BG65926B1 (enExample)
BR (1) BR0108213A (enExample)
CA (1) CA2399187C (enExample)
CY (1) CY1106992T1 (enExample)
CZ (1) CZ304258B6 (enExample)
DE (1) DE60130192T2 (enExample)
DK (1) DK1254162T3 (enExample)
ES (1) ES2292558T3 (enExample)
GB (1) GB0002952D0 (enExample)
HU (1) HUP0301817A3 (enExample)
IL (2) IL150981A0 (enExample)
MX (1) MXPA02007760A (enExample)
NO (1) NO331847B1 (enExample)
NZ (1) NZ520488A (enExample)
PL (1) PL207121B1 (enExample)
PT (1) PT1254162E (enExample)
RU (1) RU2280039C2 (enExample)
SK (1) SK11242002A3 (enExample)
UA (1) UA76949C2 (enExample)
WO (1) WO2001058934A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
MXPA03003704A (es) 2000-10-31 2004-05-04 Pharma Mar Sa Formulacion de kahalalide f.
US20050054555A1 (en) * 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
CN100396696C (zh) * 2004-04-23 2008-06-25 中国科学院海洋研究所 一种海洋绿藻在提取抗肿瘤活性环肽组分中的应用
WO2009052379A2 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
EP2252315A1 (en) * 2008-01-30 2010-11-24 Pharma Mar, S.A. Improved antitumoral treatments
EP2262522A1 (en) * 2008-03-07 2010-12-22 Pharma Mar, S.A. Improved antitumoral treatments
CN103641891B (zh) * 2013-05-23 2017-03-22 深圳翰宇药业股份有限公司 一种制备Kahalalide F的方法
CA3207643A1 (en) * 2015-09-23 2017-03-30 XWPharma Ltd. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
KR102378845B1 (ko) 2017-03-30 2022-03-24 엑스더블유파마 리미티드 이환형 헤테로아릴 유도체 및 이의 제조 및 용도
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
CN112004802B (zh) 2018-09-30 2021-12-28 凯瑞康宁生物工程（武汉）有限公司 作为神经元组胺受体-3拮抗剂的化合物及其用途
CN115244028A (zh) 2019-12-20 2022-10-25 凯瑞康宁生物工程有限公司 4-缬氨酰氧基丁酸的合成方法
AU2021292406B2 (en) 2020-06-18 2024-03-14 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
AU2021293941B2 (en) 2020-06-18 2024-03-28 XWPharma Ltd. Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
CN116261451A (zh) 2020-07-24 2023-06-13 凯瑞康宁生物工程有限公司 γ-羟基丁酸衍生物的药物组合物和药物动力学
CN115666527B (zh) 2020-10-05 2025-03-07 凯瑞康宁生物工程有限公司 γ-羟基丁酸衍生物的修饰释放组合物
TW202300139A (zh) 2021-03-19 2023-01-01 凱瑞康寧生技股份有限公司 γ-羟基丁酸衍生物的聯合釋放製劑的藥代動力學
AU2023257266A1 (en) * 2022-04-21 2024-08-22 Zevra Therapeutics, Inc. Gamma-hydroxybutyrate delivering compounds and processes for making and using them

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0610078A1 (en) * 1993-02-03 1994-08-10 Pharma Mar, S.A. Cytotoxic and antiviral compound
US6011010A (en) * 1994-02-03 2000-01-04 Pharma Mar, S.A. Cytotoxic and antiviral compound

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US39496A (en) * 1863-08-11 Improvement in ratchet-drills
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
JPS6178719A (ja) * 1984-09-25 1986-04-22 Tanabe Seiyaku Co Ltd 総合輸液剤
GR870129B (en) * 1987-01-27 1987-02-04 Giatzidis Ippokratis Stable bicarbonate - glycylglycine dialysate for hemodialysis and peritoneal dialysis
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
DK0531472T3 (da) * 1991-03-06 2003-12-01 Merck Patent Gmbh Humaniserede monoklonale antistoffer
ES2161697T3 (es) * 1991-11-19 2001-12-16 Amylin Pharmaceuticals Inc Peptidos agonistas de amilina y usos de los mismos.
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5932189A (en) * 1994-07-29 1999-08-03 Diatech, Inc. Cyclic peptide somatostatin analogs
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JP3927248B2 (ja) 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
EP0912559B1 (en) * 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6489136B1 (en) * 1997-05-09 2002-12-03 The General Hospital Corporation Cell proliferation related genes
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
WO2000031048A1 (en) * 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
CA2406743A1 (en) * 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
MXPA03003704A (es) 2000-10-31 2004-05-04 Pharma Mar Sa Formulacion de kahalalide f.
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0610078A1 (en) * 1993-02-03 1994-08-10 Pharma Mar, S.A. Cytotoxic and antiviral compound
US6011010A (en) * 1994-02-03 2000-01-04 Pharma Mar, S.A. Cytotoxic and antiviral compound

Also Published As

Publication number Publication date
RU2280039C2 (ru) 2006-07-20
CZ304258B6 (cs) 2014-02-05
UA76949C2 (en) 2006-10-16
CY1106992T1 (el) 2012-09-26
NO20023749L (no) 2002-10-07
US20080318849A1 (en) 2008-12-25
EP2258715A1 (en) 2010-12-08
ES2292558T3 (es) 2008-03-16
HK1047290A1 (en) 2003-02-14
US20040214755A1 (en) 2004-10-28
IL150981A (en) 2013-05-30
BR0108213A (pt) 2003-03-05
NO20023749D0 (no) 2002-08-08
CN1422278A (zh) 2003-06-04
BG65926B1 (bg) 2010-05-31
EP1829889A3 (en) 2007-09-26
ATE371667T1 (de) 2007-09-15
DK1254162T3 (da) 2008-01-02
KR100871489B1 (ko) 2008-12-05
EP1254162B1 (en) 2007-08-29
IL150981A0 (en) 2003-02-12
WO2001058934A2 (en) 2001-08-16
HUP0301817A2 (hu) 2003-09-29
DE60130192T2 (de) 2008-05-21
PT1254162E (pt) 2007-12-03
GB0002952D0 (en) 2000-03-29
BG107020A (bg) 2003-05-30
DE60130192D1 (de) 2007-10-11
HUP0301817A3 (en) 2011-10-28
RU2002123877A (ru) 2004-01-10
MXPA02007760A (es) 2002-10-23
CA2399187A1 (en) 2001-08-16
NZ520488A (en) 2005-03-24
PL356800A1 (en) 2004-07-12
SK11242002A3 (sk) 2003-06-03
US7482429B2 (en) 2009-01-27
EP1829889A2 (en) 2007-09-05
CZ20022740A3 (cs) 2003-01-15
WO2001058934A3 (en) 2002-03-21
AU3208601A (en) 2001-08-20
PL207121B1 (pl) 2010-11-30
KR20020092951A (ko) 2002-12-12
CN101597326A (zh) 2009-12-09
EP1254162A2 (en) 2002-11-06
CA2399187C (en) 2011-04-19
AU783542B2 (en) 2005-11-10
JP5188665B2 (ja) 2013-04-24
JP2003522198A (ja) 2003-07-22
NO331847B1 (no) 2012-04-23

Similar Documents

Publication Publication Date Title
CN101597326B (zh) kahalalide F 及相关化合物
JP3407260B2 (ja) ランチオニン架橋ペプチド
CN1443079A (zh) 抗肿瘤剂的聚合缀合物
CA2563463A1 (en) Convergent synthesis for kahalalide compounds
RU2254139C1 (ru) Средство, обладающее противоопухолевым действием
Albericio et al. Kahalalide F and related compounds
JPH07233084A (ja) 化学療法剤効果増強剤
JPH06298797A (ja) ペプチド誘導体およびその用途
JPH08225457A (ja) 癌転移抑制用組成物
HK1047290B (en) Kahalalide f and related compounds
Isidro Llobet New Protecting Groups for the Synthesis of Complex Peptides
JPH06321987A (ja) ペプチド誘導体及びその用途
White Selective, On-Resin N-Methylation of Cyclic Peptides and Implications for the Discovery of Membrane Permeable Scaffolds
JPH06239885A (ja) ペプチド誘導体及びその用途
JPH05255105A (ja) 免疫抑制剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140709

Termination date: 20150209

EXPY Termination of patent right or utility model